Cancer drug developer CG Oncology valued at $1.75 bln in strong …

Cancer Drug Developer CG Oncology Valued At $1.75 Bln In Strong …

21 hours ago

Jan 25, 2024  · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

reuters.com

Cancer Drug Developer CG Oncology Valued At $1.75 Billion In …

21 hours ago

Jan 25, 2024  · (Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new …

usnews.com

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Nasdaq

21 hours ago

Jan 25, 2024  · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as demand for new …

nasdaq.com

CG Oncology, Inc. (CGON) Stock Price, Quote & News - Stock …

21 hours ago

5 days ago  · CG Oncology valued at $1.75 bln in strong market debut. CG Oncology CGON.O notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the …

stockanalysis.com

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Yahoo …

21 hours ago

CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq.

yahoo.com

Cancer Drug Developer CG Oncology Valued At $1.75 Billion In …

21 hours ago

Jan 25, 2024  · (Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new …

yahoo.com

Cancer Drug Developer CG Oncology Targets Near $1 Bln Valuation …

21 hours ago

Jan 18, 2024  · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. Cancer drug developer CG Oncology said on …

yahoo.com

CG Oncology Targets Near $1 Bln Valuation In US IPO

21 hours ago

Jan 18, 2024  · Adds details on company's business, IPO terms in paragraphs 2-6. Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation …

nasdaq.com

CG Oncology Targets Near $1 Billion Valuation In US IPO - Yahoo …

21 hours ago

Jan 18, 2024  · The company is developing a therapy for patients with bladder cancer. Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. …

yahoo.com

UPDATE 2-Drug Developer CG Oncology Targets Up To $306 Mln …

21 hours ago

Jan 23, 2024  · Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its upsized initial public offering in New York, underscoring the resurgent …

yahoo.com

Cancer Drug Developer CG Oncology Valued At $1.75 Billion In …

21 hours ago

Jan 26, 2024  · By Pritam Biswas (Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the …

pm360online.com

Drug Developer CG Oncology Targets Up To $306 Mln For Upsized IPO

21 hours ago

Jan 23, 2024  · Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. initial public offering, ... CG Oncology would be valued at $1.1 billion in …

nasdaq.com

CG Oncology Targets Near $1 Bln Valuation In US IPO | Reuters

21 hours ago

Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. The company is developing a therapy …

reuters.com

Dublin-listed Malin’s Shot In The Arm From Share In $1.5bn Deal Will ...

21 hours ago

1 day ago  · Malin, now led by executive director Fiona Dunlevy and executive chairman Liam Daniel, sold its stake in CG Oncology, which has a bladder cancer treatment in late clinical …

irishtimes.com

CG Oncology's Lead Bladder Cancer Drug Offers Buyout …

21 hours ago

Jan 25, 2024  · A more specific example, RayzeBio, Inc. , which has an oncology drug in Phase III trials, which was valued at a similar amount of approximately $1.1 billion dollars post-IPO.

seekingalpha.com